BCL2L10 is a predictive factor for resistance to Azacitidine in: MDS and AML patients

Oncotarget

Volumn 3, Issue 4, 2012, Pages 490-501

  Cluzeau, Thomas ^a,b,c,d   Robert, Guillaume ^a,b,c   Mounier, Nicolas ^d   Karsenti, Jean Michel ^d   Dufies, Maeva ^a,b,c   Puissant, Alexandre ^a,b,c   Jacquel, Arnaud ^a,b,c   Renneville, Aline ^e   Preudhomme, Claude ^e   Cassuto, Jill Patrice ^d   Raynaud, Sophie ^d   Luciano, Frederic ^a,b,c   Auberger, Patrick ^a,b,c,d  

^a CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c Equipe labellisée par la Ligue Nationale Contre le Cancer 2011 2013   (France)

^d UNIVERSITY HOSPITAL OF NICE   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Azacitidine; Bcl2l10; Mds; Prognosis; Resistance

Indexed keywords

AZACITIDINE; BCL2L10 PROTEIN; PROTEIN BCL 2; UNCLASSIFIED DRUG; BCL2 LIKE 10 PROTEIN; BCL2-LIKE 10 PROTEIN; PHARMACOLOGICAL BIOMARKER; SMALL INTERFERING RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG RESPONSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; DRUG RESISTANCE; GENETICS; METABOLISM; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL; TRANSGENE; TUMOR CELL LINE;

AZACITIDINE; BIOMARKERS, PHARMACOLOGICAL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; TRANSGENES;

EID: 84867144917     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.481     Document Type: Article

References (36)

1. Tefferi A and Vardiman JW. Myelodysplastic syndromes. The New England journal of medicine. 2009; 361(19):1872-1885.
2. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. The lancet oncology. 2009; 10(3):223-232.
3. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL and Silverman LR. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010; 28(4):562-569.
4. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G and Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-2088.
5. Haase D. Cytogenetic features in myelodysplastic syndromes. Annals of hematology. 2008; 87(7):515-526.
6. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R, 3rd, Shen L, Nimer SD, Leavitt R, Raza A and Saba H. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106(8):1794-1803.
7. Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, Delaunay J, Salanoubat C, Visanica S, Stamatoullas A, Isnard F, Marfaing-Koka A, et al. Prognostic factors for response and overall survival in 282 patients with higherrisk myelodysplastic syndromes treated with azacitidine. Blood. 2011; 117(2):403-411.
8. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M and Ferrant A. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of highrisk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000; 18(5):956-962.
9. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D and Ebert BL. Clinical effect of point mutations in myelodysplastic syndromes. The New England journal of medicine. 2011; 364(26):2496-2506.
10. Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, Fulton R, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Kandoth C, Baty J, Westervelt P, DiPersio JF, Mardis ER, Wilson RK, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011; 25(7):1153-1158.
11. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, Harris CC, Lichti CF, Townsend RR, Fulton RS, Dooling DJ, Koboldt DC, et al. DNMT3A mutations in acute myeloid leukemia. The New England journal of medicine. 2010; 363(25):2424-2433.
12. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, Pellagatti A, Wainscoat JS, Hellstrom-Lindberg E, Gambacorti-Passerini C, Godfrey AL, Rapado I, Cvejic A, Rance R, McGee C, Ellis P, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. The New England journal of medicine. 2011; 365(15):1384-1395.
13. Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J, Krysiak K, Harris CC, Koboldt DC, Larson DE, McLellan MD, Dooling DJ, Abbott RM, Fulton RS, Schmidt H, Kalicki-Veizer J, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nature genetics. 2012; 44(1):53-57.
14. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, Sato Y, Sato-Otsubo A, Kon A, Nagasaki M, Chalkidis G, Suzuki Y, Shiosaka M, Kawahata R, Yamaguchi T, Otsu M, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478(7367):64-69.
15. Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Ades L, Fenaux P and Fontenay M. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011; 25(7):1147-1152.
16. Prebet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, Dreyfus F, Rauzy OB, Recher C, Ades L, Quesnel B, Beach CL, Fenaux P and Vey N. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011; 29(24):3322-3327.
17. Cluzeau T, Robert G, Puissant A, Jean-Michel K, Cassuto JP, Raynaud S and Auberger P. Azacitidine-resistant SKM1 myeloid cells are defective for AZA-induced mitochondrial apoptosis and autophagy. Cell cycle (Georgetown, Tex. 2011; 10(14):2339-2343.
18. Herrant M, Luciano F, Loubat A and Auberger P. The protective effect of phorbol esters on Fas-mediated apoptosis in T cells. Transcriptional and postranscriptional regulation. Oncogene. 2002; 21(32):4957-4968.
19. Luciano F, Krajewska M, Ortiz-Rubio P, Krajewski S, Zhai D, Faustin B, Bruey JM, Bailly-Maitre B, Lichtenstein A, Kolluri SK, Satterthwait AC, Zhang XK and Reed JC. Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma. Blood. 2007; 109(9):3849-3855.
20. Puissant A, Colosetti P, Robert G, Cassuto JP, Raynaud S and Auberger P. Cathepsin B release after imatinibmediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells. Leukemia. 2010; 24(1):115-124.
21. Puissant A, Dufies M, Raynaud S, Cassuto JP and Auberger P. Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells. Leukemia. 2010; 24(5):1099-1101.
22. Jacquel A, Colosetti P, Grosso S, Belhacene N, Puissant A, Marchetti S, Breittmayer JP and Auberger P. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition. Oncogene. 2007; 26(17):2445-2458.
23. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A and Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5):937-951.
24. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-4649.
25. Ke N, Godzik A and Reed JC. Bcl-B, a novel Bcl-2 family member that differentially binds and regulates Bax and Bak. J Biol Chem. 2001; 276(16):12481-12484.
26. Zhai D, Ke N, Zhang H, Ladror U, Joseph M, Eichinger A, Godzik A, Ng SC and Reed JC. Characterization of the antiapoptotic mechanism of Bcl-B. Biochem J. 2003; 376(Pt 1):229-236.
27. Zhai D, Jin C, Huang Z, Satterthwait AC and Reed JC. Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1. J Biol Chem. 2008; 283(15):9580-9586.
28. Kim JH, Yoon S, Won M, Sim SH, Ko JJ, Han S, Lee KA, Lee K and Bae J. HIP1R interacts with a member of Bcl-2 family, BCL2L10, and induces BAK-dependent cell death. Cell Physiol Biochem. 2009; 23(1-3):43-52.
29. Fabiani E, Leone G, Giachelia M, D'Alo F, Greco M, Criscuolo M, Guidi F, Rutella S, Hohaus S and Voso MT. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. Leuk Lymphoma. 2010; 51(12):2275-2284.
30. Voso MT, Fabiani E, Piciocchi A, Matteucci C, Brandimarte L, Finelli C, Pogliani E, Angelucci E, Fioritoni G, Musto P, Greco M, Criscuolo M, Fianchi L, Vignetti M, Santini V, Hohaus S, et al. Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine. Leukemia. 2011.
31. Xu JD, Furuya T, Cao XX, Liu XL, Li QQ, Wang WJ, Xu JW, Xu ZD, Sasaki K and Liu XP. Loss of BCL2L10 protein expression as prognostic predictor for poor clinical outcome in gastric carcinoma. Histopathology. 2010; 57(6):814-824.
32. Mikata R, Fukai K, Imazeki F, Arai M, Fujiwara K, Yonemitsu Y, Zhang K, Nabeya Y, Ochiai T and Yokosuka O. BCL2L10 is frequently silenced by promoter hypermethylation in gastric cancer. Oncol Rep. 2010; 23(6):1701-1708.
33. Beverly LJ, Lockwood WW, Shah PP, Erdjument-Bromage H and Varmus H. Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(3):E119-126.
34. Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A, Funato T, Yokomizo A, Naito S, Imoto I, Tsuruo T and Inazawa J. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res. 2004; 64(4):1403-1410.
35. Valdez BC, Li Y, Murray D, Corn P, Champlin RE and Andersson BS. 5-Aza-2'-deoxycytidine sensitizes busulfanresistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leukemia research. 2010; 34(3):364-372.
36. Krajewska M, Kitada S, Winter JN, Variakojis D, Lichtenstein A, Zhai D, Cuddy M, Huang X, Luciano F, Baker CH, Kim H, Shin E, Kennedy S, Olson AH, Badzio A, Jassem J, et al. Bcl-B expression in human epithelial and nonepithelial malignancies. Clin Cancer Res. 2008; 14(10):3011-3021.